A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma
about
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma
description
clinical trial
@en
klinisch onderzoek
@nl
name
A Study of Tislelizumab (BGB-A ...... hageal Squamous Cell Carcinoma
@en
type
label
A Study of Tislelizumab (BGB-A ...... hageal Squamous Cell Carcinoma
@en
prefLabel
A Study of Tislelizumab (BGB-A ...... hageal Squamous Cell Carcinoma
@en
P17
P4844
P6153
P1050
P1476
A Randomized, Placebo-Controll ...... hageal Squamous Cell Carcinoma
@en
P17
P3098
NCT03783442
P580
2018-12-12T00:00:00Z
P582
2021-03-30T00:00:00Z